A 32-year-old woman from Mumbai attends the infertility clinic with 3 years of primary infertility. She has irregular menstrual cycles (35–60 days) with hirsutism and acne. BMI is 28 kg/m². Pelvic ultrasound confirms PCOS (multiple small follicles, thickened stroma). Day-3 FSH is 7 mIU/mL, LH is 18 mIU/mL (LH:FSH ratio 2.6:1), and testosterone is mildly elevated. Husband's semen analysis is normal. She has been counselled on lifestyle modification and weight loss. After 3 months of lifestyle changes with minimal weight loss, she has not conceived. What is the most appropriate pharmacological agent to induce ovulation?

Explanation

## Clinical Context This is a case of **PCOS-related anovulation** with failed lifestyle modification. The patient requires pharmacological ovulation induction. ## Comparison of Ovulation Induction Agents in PCOS | Agent | Mechanism | Ovulation Rate | Pregnancy Rate | Adverse Effects | Notes | |-------|-----------|----------------|-----------------|-----------------|-------| | **Letrozole** | Aromatase inhibitor; ↓ estrogen → ↑ FSH | 60–70% | 25–30% | OHSS rare; no antiestrogen effects | **First-line for PCOS** | | **Clomiphene Citrate** | Selective estrogen receptor modulator (SERM); blocks negative feedback | 50–60% | 20–25% | OHSS (5–10%); thick cervical mucus; endometrial thinning | Higher OHSS risk; less effective in PCOS | | **Metformin** | Insulin sensitizer; improves ovulation in lean PCOS | 30–40% | 15–20% | GI upset; lactic acidosis (rare) | Adjunct; not first-line monotherapy | | **Gonadotropins** | Exogenous FSH; direct follicular stimulation | 70–80% | 30–35% | High OHSS risk; requires monitoring; expensive | Second-line if clomiphene/letrozole fail | ## Why Letrozole is First-Line in PCOS **Key Point:** **Letrozole is now preferred over clomiphene citrate as first-line ovulation induction in PCOS** [cite:ASRM PCOS Guidelines 2023; ACOG Committee Opinion 2023]. **High-Yield:** Letrozole advantages in PCOS: 1. **Higher ovulation and pregnancy rates** than clomiphene in PCOS (not in non-PCOS anovulation) 2. **Lower OHSS risk** — aromatase inhibitors do not suppress estrogen systemically; follicular estrogen is preserved 3. **Better cervical mucus quality** — no antiestrogen effects on cervix or endometrium 4. **Shorter half-life** — minimal systemic exposure **Mnemonic:** **LETROZOLE > CLOMIPHENE in PCOS** — **L**ower OHSS, **E**ffective, **T**hinner endometrium avoided, **R**ising FSH naturally, **O**vulation superior, **Z**ero antiestrogen effects. ## Dosing & Monitoring - **Letrozole:** 2.5 mg daily from day 2–6 (or day 3–7) of the cycle - Transvaginal ultrasound on day 10–12 to assess follicular development - Trigger ovulation with hCG (10,000 IU IM) when dominant follicle ≥ 18 mm - Timed intercourse or IUI 24–36 hours post-hCG ## Why Not the Other Options? **Clomiphene:** Although effective, it is now second-line in PCOS due to higher OHSS risk and lower pregnancy rates compared to letrozole. Reserve for non-PCOS anovulation or if letrozole fails. **Metformin:** Useful as an adjunct (especially in obese PCOS or those with insulin resistance), but monotherapy is less effective than letrozole. Typically combined with letrozole or clomiphene for synergistic effect. **Gonadotropins:** Reserved for clomiphene/letrozole-resistant anovulation or for IUI/IVF cycles. Higher cost and OHSS risk make it second-line.